Otsuka Pharmaceutical Co. Ltd. v. Par Pharmaceutical Inc.

Otsuka Pharmaceutical Co. Ltd. initiated a patent infringement lawsuit against Par Pharmaceutical Inc. in the District of Delaware (Case No. 1:13-cv-01979) on November 26, 2013. Otsuka Pharmaceutical, a major Japanese pharmaceutical company, focuses on the research, development, manufacturing, and marketing of innovative pharmaceutical products, particularly in mental, renal, and cardiovascular health areas. Par Pharmaceutical, on the other hand, is a specialty pharmaceutical company dedicated to developing, manufacturing, and distributing a broad line of generic drugs.

The core of the dispute revolves around Par Pharmaceutical's Abbreviated New Drug Application (ANDA) seeking to market a generic version of Otsuka's SAMSCA® (tolvaptan) tablet product, which is used to treat hyponatremia (low blood sodium levels). The primary patent asserted in this litigation is U.S. Patent No. 8,501,730, which broadly claims processes for preparing novel benzazepine compounds and their salts. These compounds serve as intermediates for producing pharmaceutically active 2,3,4,5-tetrahydro-1H-1-benzazepine compounds with vasopressin antagonistic activity, ultimately aimed at achieving high yield and purity on an industrial scale. The litigation was presided over by Judge Richard G. Andrews.

This case represents a typical Hatch-Waxman (ANDA) litigation, a common legal battleground in the pharmaceutical industry to protect proprietary drugs from generic competition. The District of Delaware is a critical venue for such cases, largely because a significant majority of major U.S. technology and pharmaceutical companies are incorporated there. The court is known for its experienced patent bench, making it a preferred forum for complex patent disputes. A notable aspect of this particular case is Par Pharmaceutical's initial premature and improper filing of its Paragraph IV notice, which initially led to a dismissal of related claims, but the infringement action proceeded after a proper filing. Furthermore, recent related litigation (Otsuka Pharmaceutical Co. v. Lupin Ltd., No. 24-2297 (Fed. Cir. May 21, 2026)) involving the same patent and drug affirmed a district court judgment that a generic competitor's tolvaptan ANDA process did not infringe and that asserted method claims were invalid as obvious, suggesting a broader context of generic challenges to Otsuka's tolvaptan patents.

The patent infringement litigation between Otsuka Pharmaceutical Co. Ltd. and Par Pharmaceutical Inc. (1:13-cv-01979) in the District of Delaware involved U.S. Patent No. 8,501,730. The case centered on Par's Abbreviated New Drug Application (ANDA) for a generic version of Otsuka's SAMSCA® (tolvaptan) tablets.

Here's a chronological breakdown of the key legal developments and outcome:

1. Filing & Initial Pleadings (2013-2014):

• 2013-11-26: Otsuka Pharmaceutical Co. Ltd. filed a patent infringement complaint against Par Pharmaceutical Inc. in the District of Delaware. The initial complaint also included U.S. Patent No. 5,753,677, but the focus for this summary is on U.S. Patent No. 8,501,730.
• Otsuka's lawsuit was triggered by Par's "Paragraph IV" certification, indicating that its generic product would not infringe the asserted patents or that the patents were invalid.
• 2013-12-18: Par Pharmaceutical Inc. filed its Answer and Counterclaims (D.I. 7), asserting that the claims of the '730 patent were invalid and/or would not be infringed by its generic tolvaptan tablets.
• A significant early development was Otsuka's argument that Par's initial Paragraph IV notice, sent around October 10, 2013, was "premature and improper" because Par's ANDA had not yet been accepted for filing by the FDA.
• 2014-03-10: The Court granted Otsuka's motion for judgment on the pleadings, finding Par's initial notice letter premature and improper, and dismissed all other claims of all parties without prejudice (D.I. 24).
• 2014-05-05: Par subsequently sent a proper "Second Notice Letter" (received by Otsuka on May 8, 2014) after its ANDA had been accepted by the FDA. This proper notice initiated the infringement action that proceeded in the case.

2. Pre-trial Motions & Claim Construction (2014):

• 2014-12-03: A Markman hearing was held. During the Markman hearing, the Court considered the implication of Par's premature initial filing, noting an advantage Par gained. The Court indicated an intent to push Par's infringement trial to a later date due to this premature filing.

3. Outcome:

• The final disposition of this specific case (1:13-cv-01979) is not explicitly detailed in the provided search results as a distinct trial verdict or final judgment. However, the subsequent related litigation against Lupin Limited regarding the same patent provides strong indications of the trajectory and eventual outcome concerning the '730 patent.
• Parallel PTAB IPR/PGR proceedings & related litigation: U.S. Patent No. 8,501,730 has been challenged in other Hatch-Waxman litigations involving generic versions of tolvaptan.
  • In Otsuka Pharmaceutical Co. v. Lupin Ltd. (1:21-cv-00900-RGA, D. Del., filed 2021-06-23), which involved U.S. Patent No. 8,501,730 and U.S. Patent No. 8,273,735, a bench trial was held from December 18-20, 2023.
  • 2024-07-31: Judge Andrews issued an opinion in the Lupin case, finding that the asserted claims of the '730 patent were not infringed and not invalid. However, the asserted claims of U.S. Patent No. 8,273,735 were found not infringed and invalid for obviousness.
  • 2024-08-07: A Final Judgment was entered in the Lupin case.
  • 2026-05-21: The Federal Circuit, in Otsuka Pharmaceutical Co. v. Lupin Ltd. (No. 24-2297), affirmed Judge Andrews's bench-trial judgment that Lupin's tolvaptan ANDA process did not infringe Otsuka's U.S. Patent Nos. 8,273,735 and 8,501,730. The Federal Circuit also affirmed that the asserted method claims of the '735 patent were invalid as obvious. The opinion in the Lupin case specifically noted that the district court had concluded that the product-by-process claims of the '730 patent were valid.

While the specific conclusion for Otsuka v. Par (1:13-cv-01979) isn't directly stated as a separate trial or settlement, the outcome of the Lupin case, which directly addressed the validity and infringement of the '730 patent, is highly relevant. Given that the Federal Circuit affirmed the non-infringement of the '730 patent against Lupin's ANDA product, it is probable that Par's generic product, if similar, would also be found non-infringing or that a settlement would have been reached in light of these developments. The '730 patent is listed to expire on September 1, 2026.

Otsuka Pharmaceutical Co. Ltd. was represented by counsel from Winston & Strawn LLP and Potter Anderson & Corroon LLP.

Here are some of the identified counsel:

Winston & Strawn LLP (Lead Counsel)

• George C. Lombardi
  • Role: Lead Counsel.
  • Firm Location: Chicago, IL.
  • Experience: A leading patent litigator, recognized for handling complex patent and technology litigations, including cases involving telephone and computer tech. Winston & Strawn's patent litigation practice has been recognized among the busiest law firms for patent litigation and has extensive experience before the Federal Circuit.
• Jovial Wong
  • Role: Lead Counsel.
  • Firm Location: Washington, D.C.
  • Experience: Excels in high-value patent cases related to pharmaceuticals and biotechnology.
• Chuck Klein
  • Role: Lead Counsel.
  • Firm Location: Washington, D.C.
  • Experience: Excels in high-value patent cases related to pharmaceuticals and biotechnology.

Potter Anderson & Corroon LLP (Local Counsel)

• David E. Moore
  • Role: Local Counsel.
  • Firm Location: Wilmington, DE.
  • Experience: Practices as both lead and local counsel in state and federal courts, with substantial experience in patent infringement cases, including Hatch-Waxman litigation. Potter Anderson is frequently retained as local counsel in complex patent litigation in the District of Delaware and has a strong reputation for intellectual property matters.
• Bindu Palapura
  • Role: Senior Associate, likely acting as local counsel.
  • Firm Location: Wilmington, DE.
  • Experience: Assisted David Moore in patent infringement cases, such as the AVM Technologies, LLC v. Intel Corporation case, where a jury found non-infringement for Intel.

Otsuka Pharmaceutical Co. Ltd. (In-house Counsel)
While specific in-house counsel directly appearing on the docket for this particular case were not explicitly identified in the search results, generally, Otsuka Pharmaceutical has an in-house legal team.

• Karen Gally
  • Role: Vice President & General Counsel, Otsuka America Pharmaceutical, Inc.
  • Experience: Focuses on legal issues related to clinical development, product commercialization, and corporate governance. She also worked as an Associate with Epstein, Becker & Green, representing national healthcare companies in criminal and civil investigations before joining Otsuka in 2003.
• Jennifer McGee
  • Role: Global Chief Compliance Officer.
  • Experience: Prior to joining Otsuka in 2011, she worked as a litigator at a multinational law firm, focusing on defending pharmaceutical and medical device manufacturers.

These individuals and firms were likely involved in representing Otsuka Pharmaceutical Co. Ltd. in this specific patent infringement case.

I'll research the defendant's counsel of record in this case using multiple sources.

Let me dig into the specific docket entries and Delaware counsel.

Let me verify the firm affiliation timing and find out-of-state lead counsel for Par.

Counsel of Record for the Defendant — Par Pharmaceutical, Inc.

Important sourcing caveat up front: The District of Delaware docket for Otsuka v. Par (1:13‑cv‑01979) is only partially retrievable through public sources, and several filings were sealed, so I could not pull a complete caption list or the pro hac vice motions. The two Delaware counsel below are confirmed by their signatures/ECF attributions on docket entries in this case. Par's out‑of‑state lead counsel for this specific matter is not confirmed by the sources I could retrieve, and I have not invented one.

---

1. Delaware (local) counsel of record

Steven J. Fineman — Delaware counsel / local counsel

• Firm: Richards, Layton & Finger, P.A., One Rodney Square, Wilmington, DE.
• Docket basis: ECF entries in 1:13‑cv‑01979 are attributed to "Fineman, Steven" — e.g., the stipulation to extend Par's time to file its Answering Brief to the motion for judgment on the pleadings (D.I. 14 briefing sequence), and Par's Answer and Counterclaims activity in late 2013.
• Patents/experience: His firm bio and D. Del. record show a practice focused on IP and complex commercial litigation with substantial Hatch‑Waxman experience; he co‑authored a chapter in ANDA Litigation: Strategies and Tactics for Pharmaceutical Patent Litigators and is admitted to the Federal Circuit (2004). He is also counsel of record for Par in numerous other D. Del. ANDA cases (e.g., Ferring v. Par, No. 1:15‑cv‑00173‑RGA, tried 2016, and the 2013 Reckitt Benckiser v. Par/IntelGenx matter).
• Caveat: The retrieved docket attributions do not display his firm-of-record in 2013–14. He is firmly at Richards, Layton & Finger in later related D. Del. filings (2015–2019); it is possible he appeared at a different firm earlier, and I could not verify his 2013–14 firm from the sources retrieved.

Katharine C. Lester (now Katharine Lester Mowery) — Delaware counsel / local counsel

• Firm: Richards, Layton & Finger, P.A., Wilmington, DE.
• Docket basis: Multiple docket entries in 1:13‑cv‑01979 are attributed to "Lester, Katharine" (e.g., the redacted version of Par's Answering Brief in Opposition to Otsuka's motion for judgment on the pleadings, and related service/filing items).
• Patents/experience: Long‑standing D. Del. Hatch‑Waxman practice and one of Par's regular Delaware counsel across ANDA matters (e.g., Takeda v. Par (1:12‑cv‑00419), Santarus v. Par (1:07‑cv‑00551), Prometheus v. Par (1:14‑cv‑01017), Noven v. Amneal/Actavis (2019)).

Note: Fineman and Lester frequently appear as a Delaware counsel pairing for Par in this era, which is consistent with their joint appearances in the 13‑1979 docket.

---

2. Out‑of‑state / lead counsel — NOT confirmed for this case

I could not confirm, from retrievable sources, which national firm led Par's defense in 1:13‑cv‑01979. What the record does show is that Par's recurring Hatch‑Waxman teams in this period included:

• Morgan, Lewis & Bockius LLP — Scott A. Stempel, J. Clayton Everett, Jr., Tracey F. Milich (Washington, D.C.) and Harvey Bartle IV, Francis A. DeSimone (Philadelphia) — repeatedly listed as "Counsel for Par Pharmaceutical, Inc." in Par ANDA/antitrust matters.
• Arent Fox LLP — Richard J. Berman, Janine A. Carlan, Taniel Anderson (Washington, D.C.) — Par's trial team in Ferring v. Par.
• Alston & Bird LLP — Daniel G. Jarcho, Cari K. Dawson (D.C./Atlanta) — Par/Endo counsel in other matters.

These are candidates by pattern, not confirmed appearances in 13‑1979. I would verify against the pro hac vice motions and the Answer's signature block on PACER before relying on any of them.

• In‑house counsel: No Otsuka or Par in‑house attorney appears as counsel of record in the retrievable materials for this case.

---

3. Flagged contradictions with the previously generated sections

• Plaintiff's counsel appears misattributed in the earlier "Plaintiff representatives" section. That section lists Winston & Strawn LLP and Potter Anderson & Corroon LLP for Otsuka. The documents actually filed in the related Otsuka v. Par record show Morris, Nichols, Arsht & Tunnell LLP (Jack B. Blumenfeld, Maryellen Noreika) as Delaware counsel and Cooley LLP (Jonathan G. Graves, Susan Krumplitsch, Scott Sukenick) as of‑counsel for Otsuka. The Winston & Strawn/George Lombardi attribution appears to belong to Otsuka's separate Abilify (aripiprazole) litigation, not this tolvaptan/SAMSCA matter. This should be corrected in the prior section.
• Docket numbering in the prior "Key legal developments" section is internally inconsistent (it lists D.I. 7 as the Answer, D.I. 14 as the motion for judgment on the pleadings, and D.I. 24 as the 3/10/2014 order). The retrievable docket confirms: Otsuka's motion for judgment on the pleadings (D.I. 14), Par's sealed Answering Brief (D.I. 17) and redacted version (D.I. 18), and the 3/10/2014 Order granting the motion and dismissing the alternative counts and Par's counterclaims without prejudice (civil case terminated). The Answer's exact D.I. number could not be independently confirmed.
• **Separate